Aurélien Marabelle

59PUBLICATIONS
400CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (59)

|Jul 15, 2026
HPV16 genomic status stratifies risk of disease recurrence in oropharyngeal squamous cell carcinoma.

|Jun 23, 2026
VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC.

|Apr 29, 2026
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

|Apr 01, 2026
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.

Capucine Baldini, Philippe A Cassier, Jean-Pierre Delord

|Feb 25, 2026
First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours.

Carlos Gomez-Roca, Stéphane Champiat, Francois-Xavier Danlos

|Jan 13, 2026
Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer.

Sandy Chevrier, Corentin Richard, Olivier Adotévi

Pageof 10

Frequent Collaborators

9 joint publications

François-Xavier Danlos

9 joint publications

Laurence Zitvogel

7 joint publications

Stéphane Champiat

6 joint publications

Nathalie Chaput